|
|
|
| Combined promoter hypermethylation of RASSF1A and FHIT gene in the diagnosis of non-small cell lung cancer |
| XIE Zhen1, LI Tianyue2, LIU Hongjian1, HUANG Bingtao1, ZHANG Lianguo1, ZHANG Qingguang1 |
1 Department of Thoracic surgery,Binzhou Medical University Hospital,Binzhou 256603,P.R.China;
2 Medical Examination Center, Binzhou Medical University Hospital |
|
|
|
|
Abstract Objective To determine the value of combined detection of RASSF1A and FHIT gene methylation in predicting the diagnosis of non-small cell lung cancer (NSCLC).Methods Thirty patients with non-small cell lung cancer (NSCLC) diagnosed by WHO Histopathology Standard were enrolled in the case group,and 30 cases of healthy subjects were taken as the control group.The methylation rate of RASSF1A and FHIT gene was detected by real-time fluorescence quantitative methylation specific PCR (MSP).We analyzed the effects of age,sex,histopathological type, and clinical staging on methylation,and analyzed the sensitivity and specificity of the combined detection of two genes methylation in the diagnosis of non-small cell lung cancer.Results The methylation rate of RASSF1A gene was 66.67% (20/30) in patients with NSCLC,and FHIT gene methylation rate was 60% (18/30).There was no significant correlation between the clinicopathological features and the methylation of RASSF1A and FHIT genes (P＞0.05).RASSF1A and FHIT gene methylation were independent risk factors for NSCLC.Combined detection of RASSF1A and FHIT gene methylation can significantly improve the sensitivity and specificity of diagnosis, while the positive and negative predictions have no difference.Conclusion Combined detection of RASSF1A and FHIT gene methylation can significantly improve the diagnosis of NSCLC,but there is no obvious advantage for early diagnosis.
|
|
Received: 28 April 2017
|
|
|
|
|
|
[1] 李慧,陈艳乐,常静侠,等.肿瘤标志物在肺癌诊断、病理分型和临床分期中的价值[J].中华肺部疾病杂志(电子版),2013,6(2):38-42.
[2] 丁浩,沈志高,李昊,等.血浆中多基因联合甲基化检测在肺癌诊断中的应用[J].中国病理生理杂志,2014,30(12):2128-2134.
[3] 周枫叶,杜茂林,常福厚,等.肺癌患者血浆p16和RASSF1A基因启动子区甲基化检测诊断意义分析[J].中华肿瘤防治杂志,2014,21(10):725-727,731.
[4] 朱宇敏,李坚,俞立超,等.血浆APC和DCC基因启动子甲基化测定在肺癌早期诊断中的应用[J].江苏大学学报(医学版),2015,25(1):62-67.
[5] 张文,于长海,夏晖,等.痰P16基因甲基化及K-ras基因突变联合检测对周围型肺癌的诊断价值[J].中国现代医学杂志,2012,22(8):9-13.
[6] 亢春彦,周慧聪,汤少鹏,等.血浆中检测FHIT、p16、MGMT和RASSF1A基因甲基化在肺癌诊断中的价值[J].肿瘤,2011,31(8):729-734.
[7] 王威,冯晓蕾,段晓冉,等.基于3种基因启动子甲基化联合端粒长度构建肺癌诊断支持向量机模型[J].郑州大学学报(医学版),2015,50(4):462-465.
[8] 张团结.p16基因甲基化检测在肺癌诊断中的意义[J].吉林医学,2014,35(23):5237.
[9] Deng D,Liu Z,Du Y.5-Epigenetic Alterations as Cancer Diagnostic,Prognostic,and Predictive Biomarkers[J].Adv Genet,2010,71(71):125-176.
[10] Jin M J,Kawakami K,Fukui Y,et al.Different histological types of non-small cell lung cancer have distinct folate and DNA methylation levels[J].Cancer Sci,2009,100(12):2325-2330. |
| [1] |
ZHAO Shengwen, SU Jin, DING Yuexia. Pharmacoeconomic evaluation of gefitinib in the treatment of non-small cell lung cancer[J]. 滨州医学院学报, 2019, 42(5): 373-376. |
| [2] |
GAO Zongyi,, HE Shuang, LI Yangyang, WEN Feifei, GAO Xiangqian, WU Shuhua. Expression of autophagy-associated protein LC3II in non-small cell lung cancer and its correlation withradiotherapy sensitivit[J]. 滨州医学院学报, 2019, 42(4): 267-270. |
| [3] |
JIA Teng, GU Xiaojie, LIU Hongjian, XU Haitao, ZHANG Qingguang. Postoperative adjuvant chemotherapy for stage IB non-small-cell lung cancer:A systematic review and meta-analysis[J]. 滨州医学院学报, 2019, 42(4): 281-284. |
| [4] |
. [J]. 滨州医学院学报, 2019, 42(1): 73-74. |
| [5] |
ZHANG Zhen, GAO Yuguang. Preliminary study on the effect of Odaph on enamel development[J]. 滨州医学院学报, 2018, 41(6): 455-459. |
| [6] |
MENG Wei, LIU Yongyun, JI Bing, LI Jinling, AN Xinye. VNTR analysis of molecular typing of Pseudomonas aeruginosa in nosocomial infection[J]. 滨州医学院学报, 2018, 41(6): 401-403. |
|
|
|
|
